{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:03:01Z","timestamp":1793134981148,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Antibiotic treatment for bone and joint infections generally lasts for 6 weeks or longer. Linezolid may be a good option for treating bone and joint infections, but there is an increased risk of potential serious adverse drug events (ADEs) when used for more than 28 days. The aim of this study was to obtain detailed information on the type and time to occurrence of the patient-reported ADEs, the dynamics of haematopoiesis over time, and the reasons for early discontinuation of linezolid when used for an intended maximum duration of 12 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre retrospective study was conducted at the Sint Maartenskliniek in The Netherlands. Patients were included if they were planned to use linezolid for more than 28 days. The main reason for discontinuation of linezolid, the ADE according to the Naranjo score, and the time to occurrence of ADEs were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 78 patients, drug toxicity led to early discontinuation of linezolid in 11 (14%) patients before and nine (12%) after 28 days of therapy. The median treatment duration was 42 days. Gastrointestinal intolerance (42%) and malaise (32%) were the most common ADEs. In 75% of the cases the ADE occurred within 28 days of therapy. Sixty-seven patients were able to continue linezolid beyond 28 days, 87% of whom completed therapy as scheduled. Severe cytopenia, according to the Common Terminology Criteria for Adverse events (CTCA), was observed in four patients and was reversible after discontinuation of linezolid. One patient suffered optic neuropathy related to linezolid use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Linezolid could be considered an alternative option to the current standard of IV glycopeptides for the treatment of bone and joint infection for up to 12 weeks. If patients pass the first 28 days of therapy, the likelihood of successful completion of therapy is high with a low risk of serious ADEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad276","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T11:20:35Z","timestamp":1694172035000},"page":"2660-2666","source":"Crossref","is-referenced-by-count":33,"title":["Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-6316","authenticated-orcid":false,"given":"Karin","family":"Veerman","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Sint Maartenskliniek , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Goosen","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Sint Maartenskliniek , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Spijkers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sint Maartenskliniek , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9892","authenticated-orcid":false,"given":"Nynke","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Heesterbeek","sequence":"additional","affiliation":[{"name":"Department Orthopaedic Research, Sint Maartenskliniek , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Telgt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sint Maartenskliniek , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2023110823042603600_dkad276-B1","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of the oxazolidinone antibacterial agents","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"2023110823042603600_dkad276-B2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2023110823042603600_dkad276-B3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/23744235.2019.1642510","article-title":"Linezolid in the treatment of periprosthetic joint infection caused by coagulase-negative staphylococci","volume":"51","author":"Eriksson","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2023110823042603600_dkad276-B4","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.arth.2018.09.074","article-title":"General assembly, treatment, antimicrobials: proceedings of international consensus on orthopedic infections","volume":"34","author":"Boyle","year":"2019","journal-title":"J Arthroplasty"},{"key":"2023110823042603600_dkad276-B5","author":"FDA"},{"key":"2023110823042603600_dkad276-B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol Cell"},{"key":"2023110823042603600_dkad276-B7","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01411-05","article-title":"Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones","volume":"50","author":"McKee","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110823042603600_dkad276-B8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023110823042603600_dkad276-B9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/antibiotics12040714","article-title":"Linezolid pharmacokinetics and its association with adverse drug reactions in patients with drug-resistant pulmonary tuberculosis","volume":"12","author":"Padmapriyadarsini","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2023110823042603600_dkad276-B10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1517\/14740338.3.5.405","article-title":"The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms","volume":"3","author":"Harwood","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"2023110823042603600_dkad276-B11","first-page":"61","article-title":"Optic neuropathy associated with linezolid: systematic review of cases","volume":"43","author":"Brandariz-Nunez","year":"2019","journal-title":"Farm Hosp"},{"key":"2023110823042603600_dkad276-B12","author":"UpToDate"},{"key":"2023110823042603600_dkad276-B13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5194\/jbji-6-7-2020","article-title":"Clinical use of linezolid in periprosthetic joint infections\u2014a systematic review","volume":"6","author":"Theil","year":"2020","journal-title":"J Bone Jt Infect"},{"key":"2023110823042603600_dkad276-B14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40121-014-0032-z","article-title":"A retrospective review of the clinical experience of linezolid with or without rifampicin in prosthetic joint infections treated with debridement and implant retention","volume":"3","author":"Morata","year":"2014","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"2023110823042603600_dkad276-B15","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/jac\/dku252","article-title":"Clinical experience with linezolid for the treatment of orthopaedic implant infections","volume":"69","author":"Morata","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023110823042603600_dkad276-B16","first-page":"e10890","article-title":"Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus","volume":"12","author":"Sharma","year":"2020","journal-title":"Cureus"},{"key":"2023110823042603600_dkad276-B17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J Infect Chemother"},{"key":"2023110823042603600_dkad276-B18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/antibiotics10050530","article-title":"Clinical use and adverse drug reactions of linezolid: a retrospective study in four Belgian hospital centers","volume":"10","author":"Thirot","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023110823042603600_dkad276-B19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2023110823042603600_dkad276-B20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"2023110823042603600_dkad276-B21","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"2023110823042603600_dkad276-B22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/IDR.S365371","article-title":"Linezolid-associated neuropathy in patients with MDR\/XDR tuberculosis in Shenzhen, China","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2023110823042603600_dkad276-B23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2023110823042603600_dkad276-B24","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023110823042603600_dkad276-B25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1592\/phco.27.3.476","article-title":"Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin","volume":"27","author":"Gebhart","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2023110823042603600_dkad276-B26","doi-asserted-by":"crossref","first-page":"106783","DOI":"10.1016\/j.ijantimicag.2023.106783","article-title":"LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring","volume":"61","author":"Lau","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2023110823042603600_dkad276-B27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11096-022-01379-7","article-title":"Risk factors for readmission among patients receiving outpatient parenteral antimicrobial therapy: a retrospective cohort study","volume":"44","author":"Douiyeb","year":"2022","journal-title":"Int J Clin Pharm"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/11\/2660\/52814488\/dkad276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/11\/2660\/52814488\/dkad276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T23:05:06Z","timestamp":1699484706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/11\/2660\/7264092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,8]]},"published-print":{"date-parts":[[2023,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad276","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,8]]}}}